TY - JOUR
T1 - Partial Egg Consumption Modifies the Diagnostic Performance of Allergy Tests to Predict Outcome of Double-Blind Placebo-Controlled Food Challenges to Egg
AU - Marques-Mejias, Andreina
AU - Radulovic, Suzana
AU - Foong, Ru Xin
AU - Bartha, Irene
AU - Krawiec, Marta
AU - Kwok, Matthew
AU - Jama, Zainab
AU - Harrison, Faye
AU - Ricci, Cristian
AU - Lack, Gideon
AU - Du Toit, George
AU - Santos, Alexandra F.
N1 - Funding Information:
Conflicts of interest: S. Radulovic reports salary support from grants from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of health (NIH). G. Lack reports grants from NIAID of the NIH , Food Allergy & Research Education (FARE), the Medical Research Council (MRC) & Asthma UK Centre, U.K. Department of Health through National Institute for Health and Care Research (NIHR), National Peanut Board (NPB), and The Davis Foundation, during the conduct of the study; is a shareholder in DBV Technologies and Mighty Mission Me; received personal fees from Novartis , Sanofi-Genyzme , Regeneron , ALK-Abello , and Lurie Children's Hospital , outside the submitted work. G. Du Toit reports grants from the NIAID of the NIH), FARE, MRC and Asthma UK Centre, U.K. Department of Health through NIHR, Action Medical Research and NPB; is a Scientific Advisory Board member of Aimmune; is an investigator on pharma-sponsored allergy studies (Aimmune, and DBV Technologies); and scientific advisor to Aimmune, DBV, and Novartis. A. F. Santos reports grants from MRC (MR/M008517/1; MC/PC/18052; MR/T032081/1), FARE, the Immune Tolerance Network/NIAID of the NIH, Asthma UK (AUK-BC-2015-01), Biotechnology and Biological Sciences Research Council (BBSRC), Rosetrees Trust, and the NIHR through the Biomedical Research Centre (BRC) award to Guy's and St. Thomas' National Health Service (NHS) Foundation Trust, during the conduct of the study; personal fees from Thermo Scientific, Nutricia, Infomed, Novartis, Allergy Therapeutics, Buhlmann; as well as research support from Buhlmann and Thermo Fisher Scientific through a collaboration agreement with King's College London. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
The authors would like to thank the Seal Clinical Research Facility Team, especially Helen Willis, RN; Harriet Woodhead, RN; and other research nurses for supporting study visits; Yasmin Abdat, BSc; Isabelle Olson, BSc; and Georgia Hill, BSc for study coordination; Ewa Pietraszewicz, MSc and Joanna Craven, MSc for support with data management; Charlotte Stedman, RD for help with food challenges and other dietary aspects; Lucia Jimeno-Nogales, PhD from ALK-Abello for providing allergen extracts for SPT and BAT; Sanovo Technology Group for providing the egg powder used in the baked egg challenges; and the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London and King’s College Hospital NHS Foundation Trust.
Funding Information:
This study was funded by the Medical Research Council (MRC) through MRC Clinician Scientist Fellowship MR/M008517/1 and MRC Transition Fellowship MR/T032081/1 awarded to A. F. Santos.Conflicts of interest: S. Radulovic reports salary support from grants from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of health (NIH). G. Lack reports grants from NIAID of the NIH, Food Allergy & Research Education (FARE), the Medical Research Council (MRC) & Asthma UK Centre, U.K. Department of Health through National Institute for Health and Care Research (NIHR), National Peanut Board (NPB), and The Davis Foundation, during the conduct of the study; is a shareholder in DBV Technologies and Mighty Mission Me; received personal fees from Novartis, Sanofi-Genyzme, Regeneron, ALK-Abello, and Lurie Children's Hospital, outside the submitted work. G. Du Toit reports grants from the NIAID of the NIH), FARE, MRC and Asthma UK Centre, U.K. Department of Health through NIHR, Action Medical Research and NPB; is a Scientific Advisory Board member of Aimmune; is an investigator on pharma-sponsored allergy studies (Aimmune, and DBV Technologies); and scientific advisor to Aimmune, DBV, and Novartis. A. F. Santos reports grants from MRC (MR/M008517/1; MC/PC/18052; MR/T032081/1), FARE, the Immune Tolerance Network/NIAID of the NIH, Asthma UK (AUK-BC-2015-01), Biotechnology and Biological Sciences Research Council (BBSRC), Rosetrees Trust, and the NIHR through the Biomedical Research Centre (BRC) award to Guy's and St. Thomas' National Health Service (NHS) Foundation Trust, during the conduct of the study; personal fees from Thermo Scientific, Nutricia, Infomed, Novartis, Allergy Therapeutics, Buhlmann; as well as research support from Buhlmann and Thermo Fisher Scientific through a collaboration agreement with King's College London. The rest of the authors declare that they have no relevant conflicts of interest.
Funding Information:
This study was funded by the Medical Research Council (MRC) through MRC Clinician Scientist Fellowship MR/M008517/1 and MRC Transition Fellowship MR/T032081/1 awarded to A. F. Santos.
Publisher Copyright:
© 2024 The Authors
PY - 2024/3
Y1 - 2024/3
N2 - Background: Many children are consuming some egg when they are diagnosed with egg allergy. We hypothesized that egg consumption could modify the diagnostic performance of allergy tests. Objective: To stratify diagnostic performance of tests according to egg consumption status. Methods: The BAT2 study (NCT03309488) participants underwent oral food challenge (OFC), food-frequency questionnaires, skin prick test (SPT), specific immunoglobulin E (sIgE) and specific immunoglobulin G4 (sIgG4) and basophil activation test (BAT). Results: At study entry, 45% of participants reported partial egg consumption (“consumers”) and 55% were avoiding egg strictly (“avoiders”). Avoiders had larger SPT (P < .001), higher BAT to egg (P < .001), sIgE to egg white (EW; P = .001) and to ovalbumin (OVA; P = .001), but not to ovomucoid (P = .231). Consumers had higher levels of sIgG4 to all egg allergens (P < .001) than avoiders. In consumers, the test with the best diagnostic performance was BAT (area under the curve [AUC] = .912) followed by SPT to raw egg (AUC = 0.805), EW-sIgE (AUC = 0.738), and OVA-sIgE (AUC = 0.732). In avoiders, the best tests were BAT (AUC = 0.834) and EW-sIgE (AUC = 0.833) followed by OVA-sIgE (AUC = 0.793) and SPT to EW (AUC=0.789). Using 100% sensitivity and 100% specificity cut-offs, the proportion of patients requiring OFC were 33% for BAT, 53% for SPT to raw egg, 61% for OVA-sIgE, and 73% for EW-sIgE for consumers; and 73% for BAT, 79% for EW-sIgE, and 93% for SPT to EW for avoiders. Conclusions: The diagnostic performance of tests is influenced by the immunomodulatory effect of egg consumption. BAT is the most reliable test and reduced the need for OFC, particularly in partial egg consumers.
AB - Background: Many children are consuming some egg when they are diagnosed with egg allergy. We hypothesized that egg consumption could modify the diagnostic performance of allergy tests. Objective: To stratify diagnostic performance of tests according to egg consumption status. Methods: The BAT2 study (NCT03309488) participants underwent oral food challenge (OFC), food-frequency questionnaires, skin prick test (SPT), specific immunoglobulin E (sIgE) and specific immunoglobulin G4 (sIgG4) and basophil activation test (BAT). Results: At study entry, 45% of participants reported partial egg consumption (“consumers”) and 55% were avoiding egg strictly (“avoiders”). Avoiders had larger SPT (P < .001), higher BAT to egg (P < .001), sIgE to egg white (EW; P = .001) and to ovalbumin (OVA; P = .001), but not to ovomucoid (P = .231). Consumers had higher levels of sIgG4 to all egg allergens (P < .001) than avoiders. In consumers, the test with the best diagnostic performance was BAT (area under the curve [AUC] = .912) followed by SPT to raw egg (AUC = 0.805), EW-sIgE (AUC = 0.738), and OVA-sIgE (AUC = 0.732). In avoiders, the best tests were BAT (AUC = 0.834) and EW-sIgE (AUC = 0.833) followed by OVA-sIgE (AUC = 0.793) and SPT to EW (AUC=0.789). Using 100% sensitivity and 100% specificity cut-offs, the proportion of patients requiring OFC were 33% for BAT, 53% for SPT to raw egg, 61% for OVA-sIgE, and 73% for EW-sIgE for consumers; and 73% for BAT, 79% for EW-sIgE, and 93% for SPT to EW for avoiders. Conclusions: The diagnostic performance of tests is influenced by the immunomodulatory effect of egg consumption. BAT is the most reliable test and reduced the need for OFC, particularly in partial egg consumers.
KW - Baked egg
KW - Basophil activation test
KW - Egg allergy
KW - Egg consumption
KW - Food-frequency questionnaires
UR - http://www.scopus.com/inward/record.url?scp=85183057653&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2023.12.036
DO - 10.1016/j.jaip.2023.12.036
M3 - Article
C2 - 38157981
AN - SCOPUS:85183057653
SN - 2213-2198
VL - 12
SP - 660-669.e5
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 3
ER -